Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

Teva Pharmaceutical Industries Limited’s TEVA shares have risen 21.6% in three months. Over the past few quarters, Teva has ...

Under the expanded partnership, Thermo Fisher will acquire Sanofi's sterile fill-finish and packaging facility in Ridgefield, N.J. The science-services and instruments provider said Wednesday that it ...

Thermo Fisher Scientific Inc. has expanded its strategic partnership with Sanofi to enable additional U.S. drug product manufacturing.

Thermo Fisher said on Wednesday it will buy Sanofi's manufacturing site in Ridgefield, New Jersey, to produce critical ...

Regeneron Pharmaceuticals and Sanofi are conducting a Phase 3 clinical study titled A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Invest ...

In a move to bolster its drug manufacturing capabilities in the United States, Thermo Fisher has purchased a sterile ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...